Your browser doesn't support javascript.
loading
Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.
Perez-Nieves, Magaly; Ivanova, Jasmina I; Hadjiyianni, Irene; Zhao, Chen; Cao, Dachuang; Schmerold, Luke; Kalirai, Samaneh; King, Sarah; DeLozier, Amy M; Birnbaum, Howard G; Peyrot, Mark.
Afiliação
  • Perez-Nieves M; a Eli Lilly and Company , Indianapolis , IN , USA.
  • Ivanova JI; b Analysis Group Inc. , New York , NY , USA.
  • Hadjiyianni I; c Lilly Deutschland GmbH , Bad Homburg , Germany.
  • Zhao C; b Analysis Group Inc. , New York , NY , USA.
  • Cao D; a Eli Lilly and Company , Indianapolis , IN , USA.
  • Schmerold L; b Analysis Group Inc. , New York , NY , USA.
  • Kalirai S; a Eli Lilly and Company , Indianapolis , IN , USA.
  • King S; d Analysis Group Inc. , Boston , MA , USA.
  • DeLozier AM; a Eli Lilly and Company , Indianapolis , IN , USA.
  • Birnbaum HG; d Analysis Group Inc. , Boston , MA , USA.
  • Peyrot M; e Loyola University Maryland , Baltimore , MD , USA.
Curr Med Res Opin ; 33(10): 1833-1842, 2017 10.
Article em En | MEDLINE | ID: mdl-28604111
ABSTRACT
BACKGROUND AND

OBJECTIVE:

People with type 2 diabetes mellitus (T2DM) often interrupt basal insulin treatment soon after initiation. This study aimed to describe the experiences during and after basal insulin initiation among people with T2DM with different persistence patterns.

METHODS:

Adults with T2DM from France, Germany, Spain, UK, US, Brazil, and Japan were identified from consumer panels for an online survey. Respondents who initiated basal insulin 3-24 months prior to survey date were categorized as continuers (no gaps of ≥7 days in insulin treatment); interrupters (first gap ≥7 days within 6 months of initiation and restarted insulin); and discontinuers (stopped insulin for ≥7 days within 6 months of initiation without restarting).

RESULTS:

Among 942 participants, continuers were older than interrupters and discontinuers (46, 37, and 38 years, respectively, p < .01). Continuers reported having fewer concerns before and after insulin initiation than interrupters and discontinuers, while interrupters had the most concerns. Continuers also reported fewer challenges during the first week of insulin use. Continuers were more likely to respond that insulin use had a positive impact on specific aspects of life than interrupters and discontinuers, for example on glycemic control (73.0%, 63.0%, and 61.8%, respectively; p < .01 vs. continuers).

CONCLUSION:

Among people with T2DM with different persistence patterns after basal insulin initiation there were significant differences in patient characteristics and experience during and after insulin initiation. Interrupters and discontinuers more frequently reported having concerns and challenges during the initiation process, negative impacts after initiation, and less improvement in glycemic control than continuers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Adesão à Medicação / Hipoglicemiantes / Insulina Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Adesão à Medicação / Hipoglicemiantes / Insulina Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article